Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca announced a transaction involving the sale of 15,000 American Depositary Shares by Aradhana Sarin, the company’s Executive Director and Chief Financial Officer, at a price of $88.6345 per share. This transaction, disclosed in accordance with EU Market Abuse Regulation, may have implications for stakeholders as it reflects executive-level financial decisions within the company.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £184.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the primary drivers of its stock score. The company’s robust revenue growth, high profitability, and strategic progress in key markets are significant strengths. However, the high valuation and some cash flow management challenges slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca’s innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.
Average Trading Volume: 2,075,531
Technical Sentiment Signal: Buy
Current Market Cap: £209.6B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.